This partnership includes an investment by Tate & Lyle in Zymtronix’s enzyme immobilization platform
Zymtronix, developer of revolutionary enzyme immobilization technologies, and Tate & Lyle has announced a new partnership.
This partnership includes an investment by UK based Tate & Lyle in Zymtronix’s enzyme immobilization platform that will enable the US-based company to drastically scale up its production.
Zymtronix’s enzyme immobilization platform helps to transform ingredient manufacturing by improving the productivity of biocatalysis. This is achieved through the immobilization of enzymes onto magnetic metamaterials to increase the efficiency and sustainability of enzyme-based industrial processes.
The technology, originating from Cornell University (Ithaca, NY), has broad applications in the food & beverage, flavour & fragrances, pharmaceutical, chemical and agricultural industries.
Andrew Taylor, President of Innovation and Commercial Development, Tate & Lyle said, “Consumers worldwide are looking for healthier food and drink, and we are proud to have the ingredients to help deliver just that. Improving lives for generations is at the heart of what we do, so we are excited to harness the power of Zymtronix’s enzyme immobilization platform, which will make our manufacturing processes more efficient. The platform also has the potential to accelerate our ability to make our ingredient solutions accessible to more consumers.”
Stéphane Corgié, Founder and CEO-CTO, Zymtronix said, “We are delighted to announce Tate & Lyle as our first corporate partner. Their investment will enable us to further scale up our enzyme immobilization technology, advance our processes, develop our own target ingredients, and grow our team.”
Tate & Lyle’s investment in Zymtronix will enable the company to improve and innovate upon their technology, with the goal of scaling up their platform to support process scale production. Zymtronix is initially working with Tate & Lyle to improve the use of enzymes in the production of certain ingredients and improve cost efficiency.
US based Zymtronixa is a biotech company formed in 2013 as a spin-off out of Cornell University.